ML-193 CID 1261822|cas:713121-80-3|西域试剂

ML-193 CID 1261822,96.72%

产品编号：Bellancom-110125| CAS NO：713121-80-3| 分子式：C₂₈H₂₅N₅O₄S| 分子量：527.59

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-110125	￥1000.00	杭州北京（现货）
Bellancom-110125	￥1700.00	杭州北京（现货）
Bellancom-110125	￥3500.00	杭州北京（现货）
Bellancom-110125	￥5500.00	杭州北京（现货）
Bellancom-110125	￥9500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

ML-193 CID 1261822

产品介绍

ML-193 (CID 1261822) 是一种有效和选择性的 GPR55 拮抗剂，IC₅₀ 值为 221 nM。ML-193 对 GPR55 的选择性是 GPR35，CB1 和 CB2 的 27 倍以上。ML-193 可以改善帕金森氏病 (PD) 大鼠的运动和感觉运动缺陷。

生物活性

ML-193 (CID 1261822) is a potent and selective antagonist of GPR55, with an IC₅₀ of 221 nM. ML-193 shows more than 27-fold selectivity for GPR55 over GPR35, CB1 and CB2. ML-193 can improve the motor and the sensorimotor deficits of Parkinson’s disease (PD) rats.

体外研究

ML-193 (0.01-100 μM; pretreated for 15 min) inhibits β-arrestin trafficking induced by L-α-lysophophosphatidylinositol (LPI, 10 μM) and ML186 (1 μM) with IC₅₀s of 0.22 μM and 0.12 μM, respectively.
ML-193 (0.01-10 μM; pretreated for 30 min) decreases the LPI-mediated ERK1/2 phosphorylation, with an IC₅₀ of 0.2 μM in U2OS cells.
ML-193 (5 μM; pretreated for 30 min) attenuates the GPR55 agonists induced increases in hNSCs proliferation rates^[4].
ML-193 (5 μM; 10 d) attenuates the ML184-induced increases in hNSCs differentiation^[4].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

ML193 (1 and 5 µg/rat; intra-striatal at a rate of 1 μL/min) attenuates sensorimotor deficits and slip steps, increases motor coordination in PD rats.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Wistar rats (200-250 g) were induced experimental Parkinson by 6-hydroxydopamine (6-OHDA, 10 µg/rat)
Dosage:	1 and 5 µg/rat
Administration:	Injected into the right striatum at a rate of 1 μL/min
Result:	Increased the time on the rotarod, decreased latency to remove the label and slip steps in 6-OHDA-lesioned rats.

体内研究

ML193 (1 and 5 µg/rat; intra-striatal at a rate of 1 μL/min) attenuates sensorimotor deficits and slip steps, increases motor coordination in PD rats.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Wistar rats (200-250 g) were induced experimental Parkinson by 6-hydroxydopamine (6-OHDA, 10 µg/rat)
Dosage:	1 and 5 µg/rat
Administration:	Injected into the right striatum at a rate of 1 μL/min
Result:	Increased the time on the rotarod, decreased latency to remove the label and slip steps in 6-OHDA-lesioned rats.